Several major pharma and biotech giants such as Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others are actively developing new therapies for the treatment of Progressive Fibrosing Interstitial Lung Disease. There are many more pharma companies which are conducting clinical trials for therapies of PF-ILD and IPF specific PF-ILD.
The clinical pipeline of PF-ILD looks not so robust, but the market anticipates the launch of emerging drugs in the coming years. Yet, some of the therapies carry the potential to reach the market sooner if they prove their clinical benefits in their ongoing trials. The potential drugs that can mark a significant change in the upcoming forecast period include BI 1015550, Pamrevlumab, PRM-151, Tyvaso (treprostinil), PLN-74809, and others.
DelveInsight’s “Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Fibrosing Interstitial Lung Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Progressive Fibrosing Interstitial Lung Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Progressive Fibrosing Interstitial Lung Disease (PF-ILD): An Overview
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality. Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or an auto-immune disease, such as rheumatoid arthritis, can cause it. Once lung scarring occurs, it is generally irreversible.
PF-ILDs are composed of idiopathic interstitial pneumonia, such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases, such as chronic hypersensitivity pneumonia and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation we have taken in our model includes idiopathic interstitial pneumonia (IIPs), autoimmune ILDs, hypersensitivity pneumonitis, sarcoidosis, and other ILDs.
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market Key Facts
-
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) therapeutic market size in the 7MM was USD 4,205 million in 2021.
-
The United States accounts for the highest market size of Progressive Fibrosing Interstitial Lung Disease (PF-ILD), approximately 73% of the total market size in 7MM in 2021, in comparison to the other major markets, i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
-
Among the EU5 countries, Germany had the highest market size with USD 228 million in 2021, while Spain had the lowest market size in 2021.
-
With the expected launch of upcoming therapies, such as BI 1015550, Pamrevlumab, and others, the total market size of Progressive Fibrosing Interstitial Lung Disease (IPF and Non-IPF PF-ILD) is expected to show a change in the upcoming years.
-
The estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM were 322,000+ cases in 2021.
-
The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were found to be in the US in 2021 (166,000+ cases).
-
Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,000+ cases, followed by the United Kingdom, which had diagnosed cases of 25,000+ in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
-
Japan had 31,000+ total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease for in 2021, accounting for approximately 10% of the 7MM.
-
On February 24, 2022, Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs).
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Progressive Fibrosing Interstitial Lung Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Progressive Fibrosing Interstitial Lung Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmented by –
-
Total Diagnosed Prevalent Cases of ILD in the 7MM (2019–2032)
-
Total Prevalent Cases of ILD in the 7MM (2019–2032)
-
Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019–2032)
-
Total Diagnosed Prevalent Cases of PF-ILD in the 7MM (2019–2032)
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Fibrosing Interstitial Lung Disease market or expected to be launched during the study period. The analysis covers the Progressive Fibrosing Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Progressive Fibrosing Interstitial Lung Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Progressive Fibrosing Interstitial Lung Disease Market Will Evolve and Grow by 2032 @
Progressive Fibrosing Interstitial Lung Disease Therapeutics Market Assessment
ILD and its progressing forms form a substantial proportion of disabling chronic lung diseases leading to significant morbidity and mortality. The current treatment market scenario shows that Nintedanib is the only approved treatment for chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphans of evidence-based treatments and are left with options of receiving corticosteroids and off-label immunosuppressive therapies with variable outcomes, which are the mainstay of treatment in PF-ILDs.
The Leading Companies in the Progressive Fibrosing Interstitial Lung Disease Therapeutics Market Include:
-
Boehringer Ingelheim
-
Bristol-Myers Squibb
-
FibroGen
-
Hoffmann-La Roche Ltd
-
Pliant Therapeutics, Inc.
-
United Therapeutics
-
Vicore Pharma AB
And Many More
Progressive Fibrosing Interstitial Lung Disease Drugs Covered in the Report Include:
-
BI 1015550: Boehringer Ingelheim
-
Pamrevlumab: FibroGen
-
PLN-74809: Pliant Therapeutics, Inc.
-
PRM-151 (RG6354): Hoffmann-La Roche Ltd
-
Tyvaso (inhaled treprostinil): United Therapeutics
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Fibrosing Interstitial Lung Disease Competitive Intelligence Analysis
4. Progressive Fibrosing Interstitial Lung Disease Market Overview at a Glance
5. Progressive Fibrosing Interstitial Lung Disease Disease Background and Overview
6. Progressive Fibrosing Interstitial Lung Disease Patient Journey
7. Progressive Fibrosing Interstitial Lung Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Progressive Fibrosing Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Fibrosing Interstitial Lung Disease Unmet Needs
10. Key Endpoints of Progressive Fibrosing Interstitial Lung Disease Treatment
11. Progressive Fibrosing Interstitial Lung Disease Marketed Products
12. Progressive Fibrosing Interstitial Lung Disease Emerging Drugs and Latest Therapeutic Advances
13. Progressive Fibrosing Interstitial Lung Disease Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Fibrosing Interstitial Lung Disease Market Outlook (In US, EU5, and Japan)
16. Progressive Fibrosing Interstitial Lung Disease Access and Reimbursement Overview
17. KOL Views on the Progressive Fibrosing Interstitial Lung Disease Market
18. Progressive Fibrosing Interstitial Lung Disease Market Drivers
19. Progressive Fibrosing Interstitial Lung Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Dermatophytic Onychomycosis Market
“Dermatophytic Onychomycosis Market Insights, Epidemiology, and Market Forecast 2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dermatophytic Onychomycosis market size and shares analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/